Compare BBGI & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBGI | XAIR |
|---|---|---|
| Founded | 1961 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 10.5M |
| IPO Year | 2000 | N/A |
| Metric | BBGI | XAIR |
|---|---|---|
| Price | $6.06 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 2.4M | 115.6K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $220,174,714.00 | $5,802,000.00 |
| Revenue This Year | $5.02 | $128.45 |
| Revenue Next Year | N/A | $153.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $3.67 | $1.00 |
| 52 Week High | $26.37 | $11.20 |
| Indicator | BBGI | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 28.93 |
| Support Level | $4.05 | $1.10 |
| Resistance Level | $26.37 | $1.31 |
| Average True Range (ATR) | 2.39 | 0.10 |
| MACD | 0.43 | 0.01 |
| Stochastic Oscillator | 10.17 | 5.26 |
Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.